BUY Zydus Lifesciences Limited — Pradip Hotchandani, Prudent Corporate Advisory Services
byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection
NewsNdtv-Profit·21 Aug · 2d ago
Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection
NewsCnbc-Tv18·21 Aug · 3d ago
Zydus Lifesciences Ltd received final approval from the USFDA for Ascorbic Acid Injection, including 180-days CGT exclusivity.
BSE · Company Update·21 Aug · 3d ago
Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic
NSE · Press Release·11 Aug · 2w ago
Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc
BSE · Company Update·11 Aug · 2w ago
From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook
NewsNdtv-Profit·12 Aug · 2w ago
Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.
NSE · Press Release·11 Aug · 2w ago
Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.
BSE · Company Update·11 Aug · 2w ago
Unaudited financial results for the quarter ended on June 30, 2026
BSE · Board Meeting·11 Aug · 2w ago
Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price
NewsNdtv-Profit·11 Aug · 2w ago
Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target
NewsEt-Markets·12 Aug · 2w ago
Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore
NewsEt-Markets·11 Aug · 2w ago
Zydus Lifesciences received an order from the Superintendent of Stamps, Gandhinagar, demanding recovery of ₹53.47 million in deficient stamp duty and ₹55.07 million in penalties, totaling ₹108.54 mill
BSE · Company Update·29 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.